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in the ﬁrst 6 month period resulting in $6310 in lost wages. This
loss decreased in the 2nd 6 month period as 6.2% reported
increasing work status, 88% stayed the same, and 5.2% reported
additional decreases, which continued into the ﬁrst half of year 2.
Work loss then increased to 7% until 6 years post treatment
when it slowly decreased. Hours of work loss and gain over 10
years resulted in a weighted cumulative average wage loss of
$146,500. Those at moderate risk lost more wages than high or
low risk patients. Most wages were lost by those receiving andro-
gen deprivation therapy medications alone ($190,000), while
those receiving cryotherapy had the lowest wage loss ($99,500).
Radical prostatectomy treatment alone resulted in $142,100 lost
wages over 10 years. CONCLUSION: The wages lost after treat-
ment for prostate cancer are high. This is the ﬁrst long-term look
at prostate cancer workloss. Although most wage loss occurs in
the ﬁrst six months, substantial loss continues over the next ten
years.
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OBJECTIVE: Metastatic bone disease (MBD) and subsequent
skeletal-related events (SREs) are common complications second-
ary to solid tumors. We conducted a retrospective analysis of
US health insurance claims to examine the cost of SREs among
patients with MBD secondary to breast, lung, or prostate cancer.
METHODS: Data were obtained from i3’s Lab Rx Database
from May 1, 2000 to March 31, 2005. Patients were included if
they had at least two ICD-9 diagnoses of breast, lung, or prostate
cancer; at least two diagnoses of MBD; and at least one SRE on
or after the initial MBD diagnosis. SREs were deﬁned as a patho-
logical fracture, spinal cord compression, surgery to the bone, or
radiation to the bone and were identiﬁed using ICD-9 and CPT-4
codes. Patients had to be continuously insured for at least six
months prior to their ﬁrst SRE (index date) and one month after
their index date. Descriptive statistics were calculated and the
annual cost of SREs was estimated using Kaplan-Meier curves
to adjust for censoring. RESULTS: In the study period, 3584
patients were diagnosed with breast, lung, or prostate cancer and
MBD, and 1840 (51%) experienced at least one incident SRE.
Regardless of tumor type, patients were most frequently found to
have radiation therapy (86%–89%) followed by pathological
fracture (23%–29%), bone surgery (12%–16%), and spinal cord
compression (7%–9%). The adjusted mean costs associated with
SREs in the one year after the index SRE ranged from $12,469 to
$17,408, with the highest costs associated with radiation therapy
($5930 to $7152), pathological fracture ($3179 to $6624), and
bone surgery ($2218 to $2536). CONCLUSION: This analysis
of patients with cancer-related MBD revealed that the incidence
of SREs is high and their annual economic impact is substantial
regardless of tumor type.
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OBJECTIVE: Multiple myeloma (MM) is characterized by the
accumulation of monoclonal plasma cells and osteolytic bone
destruction and is complicated by skeletal-related events (SREs)
which are associated with signiﬁcant morbidity. We conducted a
retrospective analysis of US health insurance claims to examine
the cost of SREs among patients with MM and at least one SRE.
METHODS: Data were obtained from i3’s Lab Rx Database
from May 1, 2000 to May 31, 2005. Patients were included if
they had at least 2 ICD-9 diagnoses of MM (ICD-9 203.0x);
and at least 1 SRE on or after the initial MM diagnosis. SREs
were deﬁned as a pathological fracture, spinal cord compression,
surgery to the bone, or radiation to the bone and were identiﬁed
using ICD-9 and CPT-4 codes. Patients had be continuously
insured for at least six months prior to their ﬁrst SRE (index date)
and one month after their index date. Descriptive statistics were
calculated and annual cost of SREs was estimated using Kaplan-
Meier curves to adjust for censoring. RESULTS: In the study
period, 876 patients were diagnosed with MM, and 429 (49%)
experienced at least 1 incident SRE. The mean time from MM
diagnosis to index SRE was 259 days. Pathological fracture
(60%) and radiation therapy (59%) were the most frequently
experienced SREs followed by surgery to the bone (23%).
Among these patients, 61% had 1 type of SRE, 27% had 2 types
of SREs and 12% had 3 or more. The mean charges associated
with SREs in the 1 year post SRE was $20,285, with the highest
charges associated with pathological fracture ($11,370), fol-
lowed by bone surgery ($4,020), and radiation therapy ($2,966).
CONCLUSION: This analysis of patients with MM revealed
that the incidence of SREs is high and their annual economic
impact is substantial.
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OBJECTIVE: Document total medical resource utilization and
associated costs to the Medicare system for elderly patients with
high risk (stages IIB/C, IIIA/B, IIIC) or metastatic (stage IV)
malignant melanoma. METHODS: Data was taken from the
Surveillance, Epidemiology, and End Results (SEER)-Medicare
linked database combining clinical information on incident
cancer cases in the US between 1991 and 2002 with longitudinal
(1991–2005) Medicare claims. Subjects aged 65 years with 1
stage IIB or higher melanoma diagnosis were selected. Index
dates was deﬁned as the date of the ﬁrst observed stage IIB or
higher diagnosis. Utilization and costs were descriptively ana-
lyzed for each patient from their index date until death, inter-
ruption of beneﬁts coverage (6 months), or end of the database
(December 31, 2005). RESULTS: A total of 6470 subjects met all
inclusion criteria. Stage distribution was: IIB/C (38%); IIIA/B
(46%); IIIC (1%); IV (15%). Median follow-up was 56, 39, 16,
and 6 months for each stage, respectively. On average, patients
with stage IV disease incurred 3.1 hospital days per month,
compared to 0.5, 0.6, and 1.1 days per month for subjects
with stage IIB/C, IIIA/B, and IIIC melanoma, respectively (all
P < 0.001). Mean inpatient costs for stage IV disease were $3337
per patient per month, versus $589, $880, and $1465 for stages
IIB/C, IIIA/B, and IIIC, respectively (all P < 0.001). Total health
care costs, excluding prescription drugs, were $8190 per patient
per month for stage IV disease, compared to $1703, $2536,
$4880 for stages IIB/C, IIIA/B, and IIIC, respectively (all
P < 0.001). CONCLUSION: This study provides stage-speciﬁc
estimates of resource utilization and costs in high risk and meta-
static melanoma using real-world administrative data. Findings
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